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Abstract
Background: Due to their immature immune system, neonates are at high risk of infection. This vulnerability when
combined with limited resources and health education in developing countries can lead to sepsis, resulting in high
global neonatal mortality rates. Many of these deaths are preventable. The BabyGel pilot trial tested the feasibility of
conducting the main randomised trial, with the provision of alcohol handgel to postpartum mothers for prevention
of neonatal infective morbidity in the rural community. This secondary analysis sought to evaluate the methods of
detecting infections in babies up to 3 months of age.
Methods: The pilot two-arm cluster randomised controlled trial took place in 10 villages around Mbale, Eastern
Uganda. Women were eligible and recruited antenatally if their gestation was ≥ 34 weeks. All infants of mothers
participating in the BabyGel pilot trial were followed up for the first 3 months of life. Evidence for infant infection
was collected using five different methods: clinician diagnosed infection, microbiologically confirmed infection,
maternally reported infection, a positive infection screen using the World Health Organization (WHO) Integrated
Management of Childhood Illness (IMCI) screening criteria, and reported antibiotic use identified during home and
clinic visits. These methods were assessed quantitatively regarding the detection rates of suspected infections and
qualitatively by exploring the challenges collecting data in the rural community setting.
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Results: A total of 103 eligible women participated in the BabyGel pilot trial, with 1 woman delivering twins. Of the
99 mother-infant pairs who consented to participate in the study, 55 infants were identified with infection in total.
Maternal report of illness provided the highest estimate, with mothers reporting suspected illness for 45
infants (81.8% of the total suspected infections identified). The WHO IMCI screening criteria identified 30
infants with suspected infection (54.5%), and evidence for antibiotic use was established in 22 infants (40%).
Finally, clinician-diagnosed infection identified 19 cases (34.5%), which were also microbiologically confirmed
in 5 cases (9.1%). Data collection in the rural setting was hindered by poor communication between mothers
and the research team, limited staff awareness of the study in health centres resulting in reduced safeguarding of
clinical notes, and widespread use of antibiotics prior to notification and clinical review. Furthermore, identification of
suspected infection may not have been limited to severe infections, with ambiguity and no official clinical diagnosis
being given to those identified solely by maternal report of infection.
Conclusions: A high rate of suspected infection was identified spanning the five sources of data collection, but no
ideal method was found for detection of community neonatal infection. Although maternal self-reports of infant
infection provided the highest detection rate, data collection via each source was limited and may have identified
minor rather than major infections. Future studies could utilise the IMCI screening tool to detect severe community
infection leading to referral for clinical confirmation. This should be combined with weekly contact with mothers to
detect maternally suspected illness. Obtaining more details of the symptoms and timescale will improve the accuracy
when detecting the total burden of suspected disease, and advising participants to retain medication packaging and
prescriptions will improve identification of antibiotic use.
Trial registration: Babygel pilot trial - trial registration: ISCRCTN 67852437. Registered 02/03/2015.
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Introduction
Neonatal sepsis remains a global problem, causing 15%
of all neonatal deaths [1] and claiming over 1.5 million
infant lives annually [2]. These statistics may even be
higher as neonatal mortality in developing countries is
potentially under-reported by > 20% [3]. During the first
year of life, an underdeveloped immune system renders
infants particularly vulnerable to infection [1, 4, 5]. This
vulnerability is further exacerbated in developing coun-
tries, such as Uganda, by limited resources and aware-
ness. Despite the global burden of neonatal deaths
declining, the African region still holds the highest neo-
natal mortality rate (NMR), with 30.5 per 1000 live
births [6]. Since the initiation of the Millennium Devel-
opmental Goals, Sub-Saharan Africa has witnessed the
largest relative decrease in under 5 mortality, yet still
carries the burden of half the world’s under 5 deaths and
the proportion of those deaths within the first year of life
increased [7]. The statistics highlight a demographic
which drastically demands attention. High birth rates
combined with high-risk newborn care practices and un-
hygienic environments including open rubbish dumps,
roaming animals, and standing water may contribute to
the high levels of morbidity and mortality. These settings
with proportionately high and arguably preventable neo-
natal fatalities are those where affordable, acceptable,
and sustainable interventions could yield the greatest
and most immediate gains [1].
Low household wealth, lack of maternal education, and
birth in rural settings are considered three critical deter-
minants of NMR. A recent study in Eastern Uganda found
the NMR to be higher in rural districts: 34 per 1000 com-
pared with the national NMR of 20 per 1000 (2013) [8, 9].
In Uganda, 42% of rural births are unattended [10], and
combined with lack of sanitary equipment, limited access
to clean water, potential lack of education, and unhygienic
practices, risk of infection is high [11, 12]. As many rural
communities lack disposable amounts of clean water for
hand washing, alcohol hand rub may offer the potential to
reduce the rates of neonatal sepsis and improve the status
of Africa’s NMR [13].
The BabyGel study [ISRCTN67852437] (reported else-
where) targeted a reduction in intrapartum and postna-
tal infection transmission by distributing alcohol hand
rub to pregnant women antenatally in rural communities
of Uganda for use during the birth and for 3 months
postnatally [14]. The intervention aimed to prevent
early-onset sepsis due to intrapartum maternal transmis-
sion and late-onset sepsis via human transmission of en-
vironmental pathogens.
Studies documenting rural community-acquired infec-
tion in neonates in Sub-Saharan Africa are scarce, largely
due to the difficulties in data collection. No major studies
have been done to identify rates of community-acquired
infection including sepsis in rural Uganda [15, 16], despite
88% of the population residing in rural areas [10]. The
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only related studies conducted in Uganda’s Mbarara Re-
gional Referral Hospital and Mulago Hospital aimed to
identify pathogenic organisms cultured from hospitalised
septic neonates [2, 12]. Both studies found Staphylococcus
aureus and Escherichia coli were the most common causa-
tive pathogens identified. Overall, the range of positive
cultures was limited; 65% and 63% of pathogens were
unidentifiable in Mbarara and Mulago hospitals re-
spectively [2]. These limited results are reflected in
similar studies in developing countries globally [17–20].
The obstacle to identifying the range of harmful patho-
genic organisms is rooted in the fact that investigation
strategies in the developing world are limited to blood
and cerebrospinal fluid (CSF) cultures. Polymerase
chain reaction (PCR) methods may yield greater results,
but are generally unavailable [21, 22].
Although microbiological confirmation of infection is
the gold standard for identifying neonatal sepsis, this
cannot always be achieved in developing communities
and diagnosis is often based solely on clinical signs [23].
Based on this, the Young Infants Clinical Signs Study
Group (YICSSG) identified seven clinical signs which
could be used with high sensitivity and specificity to pre-
dict requirement for neonatal referral, and WHO inte-
grated this diagnostic screening tool in their guideline
for the Integrated Management of Childhood Illnesses
[24, 25]. The validated IMCI screening form and diag-
nostic signs have since been adapted, utilised, and tested
in many developing countries globally in rural settings
to identify suspected infection [26, 27]. This screening
tool was utilised in the BabyGel study to assess infec-
tious morbidity.
This paper reports a secondary analysis of the pilot
trial, comparing the various methods for identifying sus-
pected infection in the initial 3 months of life in rural
Ugandan communities.
Methods
Study setting and participant recruitment
The BabyGel pilot trial was conducted in 10 villages
around Mbale, Uganda. Consent was sought from all
mothers who were estimated to be at > 34 weeks’ gesta-
tion at the time of recruitment and resided in a partici-
pating village. A 3-month recruitment period was
considered adequate by the investigators to assess the
ability to recruit women to the study and resulted in re-
cruitment of 103 women (who went on to deliver 104
newborns).
Study timeline
A timescale of 3 months was chosen to follow up the
newborns/infants. This was chosen as a balance between
the duration of time over which the provision of alcohol
hand rub could be sustained and the period during
which neonatal infection rates are highest and infant im-
munity is lowest. Vulnerability to infection is greatest
during that early period, with one third of all child
deaths occurring during the initial month of life [28].
Data collection
The gamut of suspected infection was identified using
five methods of data collection: community-based IMCI
screening forms, clinician-diagnosed infection detailed
in hospital notes, microbiologically confirmed infection,
and maternally reported infection and antibiotic use.
The data collected was utilised to calculate the burden
of disease amongst the participating infants in both the
control and intervention groups.
Screening for suspected infection was carried out by
the research team at the place of birth, in the village
health worker (VHW) or parent’s home, hospital, or
health centre on every participating infant at day 1 and
day 90 following delivery, as well as any infant with sus-
pected illness in the interim (day 2–89). A day 1 screen-
ing form or interim visit/day 90 screening form which
incorporated the WHO Integrated Management of
Childhood Illness (IMCI) criteria for possible infection
was utilised (Fig. 1) [29]. The use of a validated screen-
ing form standardised the information gathered, to iden-
tify what constituted an infected child and thereby
prevent bias due to researchers subjectively diagnosing
infection. The VHWs were trained for 1 day in the
protocol and use of the screening form at the start of
the study, and training was re-capped each time they
returned a completed screening form to the research as-
sistants. The IMCI screening form was utilised as the
gold standard for infection data collection, allowing
comparison with the other methods of detection.
A combination of passive and active surveillance
methods was used to obtain the greatest amount of data
possible. Participating women could contact the research
team or an allocated VHW following delivery or if they
suspected illness in their baby at any time postnatally,
whilst the VHW and research team actively contacted
the women around the expected due date for delivery,
and 90 days from the day of birth. VHWs were encour-
aged to visit the mothers and complete the screening
form twice weekly in the first month, and then weekly
thereafter, although this was often not done. Midwives at
the local health centres also notified the research team
of inpatient births.
Screening data was collected electronically on hand-
held Samsung Galaxy S4 mobile smart phones using an
electronic data capture system—the ‘Open Datacollect
Kit’ (ODK). Researchers scanned the participants’ indi-
vidual barcode or entered their ID manually into the ap-
propriate electronic form, prior to conducting the
interview. On completion, the form was encrypted and
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transferred (via a server in Mbale) in real time to a data
analyst at the University of Liverpool.
Any positive response to a question was considered an
indicator of infection in the infant, and they were appro-
priately referred to the local health centre or Mbale Re-
gional Referral Hospital (MRRH) where a clinical
diagnosis, samples for culture, and treatment could be
obtained. Where possible, clinical notes delineating the
physician diagnosis and any associated microbiological
evidence were then collected for all infants admitted.
Where expertise and facilities allowed, blood samples
were collected, alongside stool and pus samples where
relevant. Samples were analysed at the microbiology la-
boratory of Busitema University. Blood was aseptically
collected into BACTEC bottles using the vacutainer sys-
tem by trained laboratory personnel and loaded with in-
oculum into the BACTEC 50 blood culture system for
auto-detection of microbial growth. Those with positive
growth were sub-cultured on MacConkey agar (Oxoi-
d-UK), blood agar, and chocolate agar (Oxoid-UK) for
maximum recovery of bacteria. A portion of the stool
samples were inoculated in selenite F broth, incubated at
37 °C for 18 h, and then sub-cultured on XLD agar and
MacConkey agar. The other portions were directly inoc-
ulated on XLD agar and MacConkey agar. Pus swabs
were inoculated on blood agar, MacConkey agar, and
chocolate agar. All the inoculated plates were incubated
at 37 °C for 18–24 h under ambient air except for choc-
olate agar plates which were incubated at 37 °C in an an-
aerobic jar. Isolated bacteria were identified using
standard biochemical methods and sensitivity tested
against a range of locally available antibiotics. Samples
were not obtained from infants with antibiotic exposure
prior to health centre admission as there is a low detec-
tion rate with such samples.
Data was collected on the use of antibiotics. The Baby-
Gel pilot trial interim screening form specifically asked
respondents to name any medicines that had been used,
and VHWs and/or other health workers were also asked
to comment on antibiotic use in free text on the screen-
ing tool. Clinical notes were also reviewed to collect
written data on drugs administered to the infant during
and prior to admission. When mothers retrospectively
commented on antibiotic use, they were asked if they
had kept the box or prescription for confirmation, or if
they could recall the drug administered to the child;
cases of uncertainty were not counted, e.g. ‘baby was
taken to a nearby drug shop and dispensed unknown
syrup’.
The same screening form was used at day 90 and dur-
ing the interim period; it questioned: ‘Has your baby
been unwell since the last visit?’, Has your baby ever
been admitted to hospital since the last visit?’, ‘How
many times?’ (for each), and ‘For how long did your baby
spend in the hospital?’. These questions were designed
to capture any infants who had been ill but had screened
negative or in whom clinical notes were not collected.
Further details to elaborate were also recorded in a
free-text box completed by the interviewer at the end of
the form.
Finally, an international standard verbal autopsy ques-
tionnaire was utilised to determine the cause of death in
any infant that died during the study.
Ethical considerations
This secondary analysis was part of the BabyGel pilot trial,
granted ethical approval by the ‘University of Liverpool
Research and Ethics Committee’ in the UK, the ‘MRRH
Institutional Review Committee’ in Mbale, and the
Uganda National Council for Science and Technology
Fig. 1 The IMCI screening criteria for infection
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(RETH000808, REIRC IN – COM 011/2015 and HS1768
respectively).
Participant consent interviews were conducted in the
language most comprehensible to the subject (local lan-
guage Lumasaba or English), and written consent was
subsequently obtained.
Results
A total of 103 mothers consented to participate in the
study (104 infants—including one set of twins). Three
stillbirths, an early neonatal death with no screening,
and a mother who withdrew from the study with no
screening were all excluded; one late neonatal death
with completed day 1 screening details and a
mother-infant pair who relocated after completing the
day 1 screening were retained in the statistical analysis.
Thus, a total of 98 women (99 mother-infant pairs)
were included, with 96 women (97 mother-infant pairs)
completing 3 months of follow-up (Table 1). The mean
age of the women who participated in the study was
24.9 years (mean (s.d.) 5.7 [15–38]).
The study identified evidence for suspected infection
in 55 (55.6%) of the 99 infants followed up, of which 27
and 28 infants were in the control and interventions
arms respectively. The clinical comparative outcomes
are reported elsewhere. Figure 2 summarises the results
of the study. Considering the 99 infants followed up, in
total, 45 infected infants (45.5%) were identified by ma-
ternal report, 30 (30.3%) screened positive, and clinical
notes were obtained for 19 (19.2%) (of which 5 cases
(5.1%) were supported by microbiological evidence). In
some cases, infection was positively identified from mul-
tiple sources; however, evidence from all three of these
sources was only obtained for 12/55 (21.8%) of the total
infants identified with suspected infection (Fig. 3). There
were no infection outbreaks in the region at the time of
the study.
Of the 55 infants with evidence of suspected infection,
IMCI screening forms were positive for indicators of in-
fection for 30 infants (54.5%); 22 (40%) infants had a sin-
gle positive screen and 8 (14.5%) had two positive
screens during the follow-up period (mean (s.d.) number
of positive screens per infant: 1.27 (0.45)). There were 8
positive screens at the day 1 follow up, 3 at the day 90
follow up, and 27 screened positive for suspected infec-
tion during the interim period (Table 2). Reliable dates
were obtained for only 11 of the 27 positive screens dur-
ing the interim period; of these, 2 (18.2%) occurred in
the first 14 days after birth, 4 (36.4%) occurred between
day 15 and day 30, and the remaining 5 (45.5%) during
months 2 and 3 of the follow-up period (mean (s.d.) age
of infants at positive screen: 40 (32) days). A relapse was
considered any second positive screen < 7 days after the
first positive screen, and a new episode of infection was
any second positive screen > 7 days after the first. Of the
8 babies with two positive screens during the study, 3
screened positive at day 1 and during the interim (2 un-
reliable dates and 1 relapse), 2 screened at day 90 and
during the interim (1 unreliable date and 1 episode of
new infection), and 3 screened positive twice during the
interim period (2 unreliable dates and 1 relapse).
Table 3 illustrates the various fields which indicated
infection in infants on each screening form. The
remaining 25 infected infants were never captured on
any screening form, but were identified via clinical notes
and maternal report. In this way, successful use of the
IMCI screening form criteria was limited; some of these
infants screened negative yet were subsequently referred
to a health centre and clinically diagnosed with sus-
pected infection.
Medical notes were collected for 19 infants who were
clinically diagnosed with infection (Table 2), of which 12
had also screened positive for indicators of infection on
a screening form (Fig. 3). The VHWs and study re-
searchers could not attend for referral with all infants
who screened positive, limiting the amount of medical
notes that could be traced. One neonate died within the
Table 1 Demographics of study participants
N (%)
Total participants 103
Age*
15–20 25 (24.3)
21–30 56 (54.4)
31–40 21 (20.4)
Mean age 24.9
Marital status
Single 22 (21.4)
Married 80 (77.7)
Divorced/separated 0
Widowed 1 (1.0)
Highest level of education
No formal education 3 (2.9)
Did not complete primary education 52 (50.5)
Completed primary (PLE) 32 (31.1)
Completed ordinary or advanced level (UCE/UACE) 14 (13.6)
Completed diploma or degree 2 (1.9)
Primary occupation
Peasant farmer, no paid employment, or housewife 95 (92.2)
Student 3 (2.9)
Business woman 2 (1.9)
Professional 1 (1.0)
Others 2 (1.9)
*Data missing on 1 woman
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first month. The suspected cause of death was ‘sepsis’
based on the information gathered in the clinical notes
and verbal autopsy form.
It was not possible to obtain lab samples for all 19 in-
fants due to limited resources and staff at the health
centres. In total, 16 culture samples were obtained from
10 of these infants, of which 5 samples returned positive
results (Table 4). The most common pathogen cultured
was Staphylococcus spp. (60%), and both Escherichia coli
and Staphylococcus aureus were cultured once each
(20% respectively). As anticipated, positive cultures were
only obtained in 31% of samples: 3 blood samples, 1
stool sample, and 1 pus sample. No CSF samples were
drawn (due to limited resources at the point of care). In
cases whereby multiple samples were taken from infants
(e.g. blood and pus), growth only occurred in 1 sample.
A total of 45 mothers reported that their child had
been infected on the 90-day IMCI screening form or in-
terim form. Of these, 21 infants also screened positive
on a screening form; therefore, the question captured 24
cases whereby infants may have been ill but were not
additionally screened when ill/did not screen positive on
a screening form (Fig. 3). Mothers reported 106 counts
of illness in total, due to some infants falling ill on mul-
tiple occasions. The IMCI screening forms therefore
failed to identify 69 occasions in which infants may have
been infected. Data collected via maternal reports of in-
fection identified 45/55 (81.8%) of the total infants with
suspected illness.
There is evidence for 22 infants being administered
antibiotics, in some cases prior to hospital admission.
Table 5 indicates which infants were subject to antibiotic
use and where this information was gathered from, and
it also lists the types of antibiotics in use and in what
frequency used. In total, 8 infants were also clinically di-
agnosed with malaria (Table 2). All were in the
post-neonatal period and received antimalarial medica-
tion (14.5% of the total with suspected infection); 3 cases
were confirmed with a rapid diagnostic screening test,
but there was no evidence of diagnostic testing for the
other 5 infants. Co-infection with pneumonia occurred
in 1 infant, and a skin infection in another.
A total of 15 mothers were known to carry HIV, of
which 4 were on co-trimoxazole prophylaxis. None of
Fig. 2 A flow diagram to illustrate the study results
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the babies of HIV-infected women received prophylaxis.
The infection rate in babies of HIV-infected mothers
was 73% compared to 57% in those of non-infected
mothers (p = 0.236, chi-squared test).
In order to calculate the sensitivity and specificity,
clinical diagnosis was utilised as the gold standard (des-
pite there being 80.8% of missing results), assuming that
all missing results were negative. With these provisos,
the results were:
Maternally reported infection: sensitivity 18/19 (94.7%:
74.0% to 99.9%), specificity 53/80 (66.3%: 54.8% to
76.4%); positive IMCI screen: sensitivity 12/19 (63.2%:
38.6% to 83.7%), specificity 62/80 (77.5%: 66.8% to
86.1%); evidence of antibiotic use: sensitivity 17/19
(89.5%: 66.9% to 98.7%), specificity 75/80 (93.8%: 86.0%
to 97.9%).
Discussion
Summary of results
Utilising all five methods of data collection, suspected
infection was identified in 55.6% of the study partici-
pants, a high figure especially when considering some of
these infants were ill on multiple occasions. None of the
methods of data collection successfully identified all
cases of suspected neonatal infection. The IMCI screen-
ing forms successfully identified infection in 30.3% of
the total study participants and 54.5% of the total num-
ber of infants with suspected infection. Evidence for in-
fection from clinical notes was found for only 34.5% of
the infants with suspected infection, and microbiological
evidence was obtained for only 9.1% of the total sus-
pected with infection. Similar to reports in previous
studies, Staphylococcus spp. and Escherichia coli were
the most common causative pathogens identified [2, 12].
Maternal report of infection captured the greatest
amount of data, as mothers reported illness for 81.8% of
the total presumed infected infants. Finally, evidence for
antibiotic use was only found in 40% of the total infected
infants.
Whilst it is desirable to have the sensitivity and specifi-
city for each method of data collection, this had to be cal-
culated (and must also be interpreted) with great caution.
The analysis was calculated on all 99 infants (including
those who did not test positive) and assumes, probably er-
roneously, that the absence of a positive result for any test
method equated to a negative test result. Furthermore, the
evidence available in the clinical notes had to be utilised
as the gold standard and that itself is suspect.
Comparison to other studies
The main difference between this study and others was
the prospective rather than retrospective element. A
Fig. 3 Venn diagram indicating the various sources by which presumed infection was identified in participants
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recent cross-sectional study in Eastern Uganda involved
conducting face to face interviews with 2237 women
who had delivered in the past 12 months, to determine
the neonatal mortality rate and influential factors [30].
The retrospective nature of the study meant it was
therefore subject to recall bias, and the sole reliance of
maternal assessment of ‘danger signs at birth’ (e.g. ‘yel-
low skin’, ‘difficulty breathing’) was arguably subjective
and potentially unreliable. A similar community-based
prospective cohort study was carried out in Mbale, East-
ern Uganda, to determine perinatal mortality and risk
factors of perinatal death for 7 days postnatally in 835
women [9]. There were 34 perinatal deaths (18 excluding
stillbirths), none of which were officially registered or
had death certificates (again illustrating the difficulty of
monitoring infection and NMR using the accepted esti-
mated statistics for the country). Again, the women were
interviewed within 4 weeks of delivery to recall their
antenatal care attendance, socio-demographic character-
istics, and infant mortality. Other studies which consid-
ered community infection in neonates generally required
the women to attend hospital or antenatal clinics for
data collection, due to the difficulty of regularly moni-
toring infants in the community home.
Limitations of study
The prospective element of this study meant data had to
be collected in real time, and the obstacles to data col-
lection faced in this trial highlight why there is a paucity
of published research on rural Ugandan mothers and
children. Numerous challenges prevented widespread
use of the screening forms. The VHWs were not always
notified when infants fell ill and may not have been
available to visit the mother at home. This likely resulted
in cases whereby infection was missed. Mothers also
often bypassed the study screening process, attending
hospital or health centres directly with their children
without notifying the research team, presumably due to
concerns about their baby’s health and to avoid delays in
seeking care. Others screened positive on the IMCI
form, but there was no record of their subsequent
Table 2 Results of the study for all participants
N % (95% CI)
Total maternal recruits 103
Withdrawals 2
Stillbirths 3
Neonatal deaths 2
Total infants screened + followed up* 99
Any evidence of infection 55 55.6 (45.2:65.5)
Positive screen
Day 1 8 8.1 (3.6:15.3)
Interim 27 27.3 (18.8:37.1)
Day 90 3 3.0 (0.6:8.6)
Day 1 and/or interim and/or day 90 30 30.3 (21.5:40.4)
Clinical diagnosis of infection (from clinical notes) 19 19.2 (12.0:28.3)
Oomphalitis 1 1.0 (< 0.1:5.5)
Pneumonia 2 2.0 (0.2:7.1)
Diarrhoea 1 1.0 (< 0.1:5.5)
Neonatal septicaemia 6 6.1 (2.3:12.7)
Upper respiratory tract infection 3 3.0 (0.6:8.6)
Skin pustules/infection 3 3.0 (0.6:8.6)
Evidence from all three sources 12 12.1 (6.4:20.2)
Unspecified source 3 3.0 (0.6:8.6)
Microbiological evidence 5 5.1 (1.7:11.4)
Maternally reported infection 45 45.5 (35.4:55.8)
Received antibiotics 22 22.2 (14.5:31.7)
Infants receiving antimalarial medication 8 8.1 (3.6:15.3)
CI confidence interval
*Includes 1 set of twins, 1 neonatal death (screened at day 1), and 1
withdrawal (screened at day 1)
Table 3 Criteria indicating presumed infection in infants (based on IMCI screening forms)
Day Difficulty feeding Convulsions Moving only when
stimulated /not at all
Chest wall
indrawing
Fast respiratory
rate
High axillary
temperature
Low axillary
temperature
1 5 0 0 0 0 4 0
90 1 1 1 1 0 2 0
Interim (day 2–89) 9 3 2 5 19 11 1
Totals 15 4 3 6 19 17 1
Table 4 Outcome for culture samples obtained
Organisms N (%)
Total samples taken 16
Blood samples 10 (62.5)
Pus swab 2 (12.5)
Stool sample 4 (25.0)
Cerebrospinal fluid 0
Total positive samples 5 (31.3)
Positive blood cultures Staphylococcus spp. (3) 3 (18.8)
Positive pus swabs Staphylococcus aureus (1) 1 (6.3)
Positive stool samples Escherichia coli (1) 1 (6.3)
Cerebrospinal fluid 0
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attendance at the study health centres as should have
happened per protocol. Mothers may have taken their in-
fants to local pharmacies or private clinics to prevent
the informal charges that are sometimes demanded by
health centre staff. Furthermore, mothers were some-
times absent from home during day 1 or 90 screening,
and others failed to notify researchers that their child
had been born for some time. All these presented enor-
mous difficulties in collecting accurate, reliable data on
infant infection.
Although clinical notes were obtained where possible
from hospitals and health centres following referral, de-
lays in researcher notification meant that clinical notes
were often no longer traceable. Finite members of staff
at the health centres and hospitals were notified of the
study, and therefore, the safeguarding of participant
notes was limited by staff awareness. This was an im-
portant learning point from the pilot study and may
have been exacerbated by parental refusal to attend hos-
pital following referral which has been documented in
previous community-based studies [20, 31].
Unlike the IMCI screening forms, and clinical or
microbiological data which made diagnoses in real time,
maternal report of infection captured the greatest num-
ber of infants with suspected infection, but was subject
to recall bias. Likewise, data obtained on antibiotic ex-
posure was occasionally gathered from free-text com-
ments on the screening forms and therefore also subject
to recall bias.
Furthermore, the IMCI form is a validated tool for se-
vere illness, whilst the other methods used in this study
are more specific for infections. This makes comparison
of infection rates challenging. Mothers were asked: ‘Has
your baby been unwell since the last visit?’ ‘How many
times has baby been unwell?’ and ‘Has your baby ever
been admitted to the hospital since the last visit?’. Be-
sides recall bias, the closed questions neither establish
the severity of the suspected infection nor the time
period. Thus, it would be possible for the quoted rates
to include both minor infections and relapses rather
than individual episodes of severe illness. Only 18 of the
45 infants (40%) identified via maternal report were clin-
ically diagnosed. This can be partially explained by lack
of care-seeking at health facilities and the difficulty in
collecting clinical documentation from busy health cen-
tres and might also indicate limitations in maternal rec-
ognition and report of severe infection.
Collecting hard evidence for infant infection was chal-
lenging. Whilst clinical notes reported infections ranging
from neonatal septicaemia to skin pustules and diar-
rhoea, microbiological evidence for infection was very
limited. Although funding for tests was made available
for the study, established local practice is not to rely on
microbiological testing but rather to provide empirical
treatment. Furthermore, in Mbale, antibiotics can be ob-
tained with ease over the counter from local sources
without a qualified diagnosis being made. Antibiotic use
could therefore not be confidently utilised as an indica-
tor of infection (and especially severe infection) in par-
ticipants, even though the information was easily
obtained retrospectively from mothers.
The free-text comments documented on the screening
forms indicated liberal use of freely available antibiotics
within the rural setting without a prescription. Antibiotic
exposure prior to admission meant limited samples
could be obtained from infants, resulting in few cases of
illness with microbiological evidence. Although 31% of
culture samples obtained were positive (comparable to
the 35 and 37% obtained in the Mbarara Regional Refer-
ral Hospital and Mulago Hospital studies respectively)
[2, 12], only 10 infants with suspected illness had sam-
ples taken for culture. Furthermore, the process of trans-
porting samples was not without error: one baby had
samples taken for complete blood count (CBC) with
blood culture and sensitivity which was delivered to the
Table 5 A table indicating antibiotic use in all infants with
suspected infection
N %
Total participants with infection 55 100
Total antibiotic exposure 22 40.0 (27.0:54.1)
Sources of evidence for antibiotic use
Clinical notes 17 30.9 (19.1:44.8)
Direct question addressing use of
any medication on IMCI form
3 5.5 (1.1:15.1)
Comments on antibiotic use (free
text)
19 34.5 (22.2:48.6)
Total antibiotic exposures 52* 100
Named antibiotic
Amoxicillin 8 15.4 (6.9:28.1)
Ceftriaxone 10 19.2 (9.6:32.5)
Gentamycin 7 13.5 (5.6:25.8)
Metronidazole 3 5.8 (1.2:15.9)
Ampiclox 4 7.7 (2.1:18.5)
Nalidixic acid 1 1.9 (0.1:10.3)
Ampicillin 4 7.7 (2.1:18.5)
Cloxacillin 2 3.8 (0.5:13.2)
Benzyl penicillin 2 3.8 (0.5:13.2)
Co-trimoxazole 6 11.5 (4.4:23.4)
Neomycin 1 1.9 (0.1:10.3)
Amikacin 1 1.9 (0.1:10.3)
Mupirocin 1 1.9 (0.1:10.3)
Tetracycline 1 1.9 (0.1:10.3)
Erythromycin 1 1.9 (0.1:10.3)
*Many babies had more than 1 antibiotic
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hospital where there were no personnel to receive it.
The sample subsequently haemolysed and was rejected
due to a public holiday resulting in the sample
remaining at room temperature for > 48 h.
A further reason for the limited number of samples
was the lack of skilled staff. Hospitals and health centres
in Uganda are often under-staffed, and therefore, neces-
sary tests and investigations cannot be carried out as re-
quired, or advised by local protocol. Arguably, this is
one of the greatest challenges of carrying out research of
this type in this environment. With appropriate funding,
it would be possible to set up a study in a high-quality
European standard paediatric ward with all the associ-
ated resources, but this would ultimately alter the study
setting and prevent this being a pragmatic study.
Strengths of study
The study had a high follow-up rate, with all participants
being tracked to day 90 postnatally, except the women
who withdrew their consent or relocated and those with
perinatal deaths. The prospective format gives a variety
of strengths: the potential for clear temporal chronology
to link the outcome to the exposure, limited risk of re-
call bias due to rapid assessment with the IMCI screen-
ing forms, and clinical or microbiological diagnosis in
real time. The variety of methods utilised for data collec-
tion meant that a spectrum of illness was captured. In
cases whereby multiple methods successfully identified
singular episodes of infection, the combined data was
complementary, creating a sound clinical picture, which
could be utilised to differentiate severe from minor
infection.
Future recommendations
In future studies, alterations must be made to the
methods of data collection and the details gathered. The
choice of method will depend on a balance of cost, feasi-
bility, and acceptability. Unless all methods measure se-
vere infection only, differences in infection risk will be
incomparable; limiting the study outcome to major in-
fections would permit comparative analysis. The IMCI
screening form should only identify severe infection, as
should the clinical notes of those presenting directly to
health care providers. In contrast, the maternal report of
infection captured a huge number of infants with poten-
tially minor or suspected infections. This was com-
pounded by the difficulty of VHWs accessing the
community homes making it difficult to verify maternal
reports. In order to reduce recall bias and ensure the in-
fections being identified are severe, the maternal question-
naire about recent infections should include greater detail
on the symptoms, signs, date, and length of illness. Regu-
lar, weekly communication with participants via a toll-free
number would improve communication between the
researchers and mothers to determine if the child has
been ill in the past week (whilst also reducing the risk of
recall bias). A researcher could attend the home to assess
the ill child or visit the health centre/hospital the mother
attended during the week to collect clinical notes if the
baby was admitted, to ensure as many infants with sus-
pected infection are captured as possible. Particular atten-
tion should be paid around the expected date of delivery
and final follow-up, with frequent communication to guar-
antee adequate data collection.
To improve the collection of both clinical and micro-
biological data, improved communication between the
health centres and laboratory alongside more reliable
services will be required for future studies. Although
multiple samples were obtained from infected infants,
only singular samples yielded results, confirming the im-
portance of obtaining multiple samples where possible
and relevant. This thorough method optimised the
chance of achieving measurable pathogenic growth and
should continue to be utilised in future studies. As many
members of clinical staff as possible should be notified
of the research taking place at the health centres and
local hospital, so they have an awareness of the mothers
participating and can notify researchers, keeping notes
and samples relating to the participants safe. Where
screening forms result in a referral to a health centre or
hospital, researchers should attend with the infant in
order to collect the clinically relevant notes and make
the health practitioners aware that the infant is partici-
pating in the study.
The challenge of antibiotic use prior to hospital admis-
sion and self-prescribed antibiotic use within the
community is difficult to address. During the 90-day
interview, numerous mothers described occasions on
which their child had been ill, and they had
self-medicated them and/or not notified the VHWs. Fu-
ture studies could monitor antibiotic use reported both
verbally and with evidence of prescription or drug pack-
aging to more accurately capture the cohort of infants
with suspected infection. Administration of antibiotics is
a useful indicator of how ill the mother deems their
child to be, particularly as a limitation of maternal report
of infection is the risk of identifying minor illness rather
than severe infections. The benefit of capturing data
through maternally reported antibiotic use includes
identifying suspected infection regardless of where the
care was sought and would be helpful to monitor as a
public health outcome given the financial cost of anti-
biotic use and development of antibiotic resistance,
which is a growing international concern [20, 32]. Draw-
backs include a potential overestimation of the fre-
quency of true infections and difficulty in ascertaining
which drugs were administered as often drugs are pro-
vided over the counter without a prescription. This
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might be addressed by ensuring prescriptions and pack-
aging are retained for inspection by the research team. Al-
ternatively, to reduce the risk of overestimation, evidence
for antibiotic use could be restricted to that provided by
qualified health care professionals. The downside would
be that it might also result in cases being missed. There is
currently a paucity of data on the use of antibiotics within
Uganda’s rural communities [33], and monitoring this in
future would be valuable [34, 35].
Conclusions
Rural communities are often relatively inaccessible and
isolated, and antibiotics are frequently obtained over the
counter without a prescription. Formal clinical diagnoses
and laboratory-based evidence are rare, due to antibiotic
use prior to admission and limited medical and labora-
tory facilities. There were limitations to each method of
infection ascertainment, yet overall, each method cap-
tured some evidence for suspected infection, in some
cases creating a clinically complementary picture. It fol-
lows that each method of data collection utilised in this
study could be beneficial if used in future studies with
some considerations. Future studies should focus on the
clinical diagnosis of severe infection. The IMCI screen-
ing tool is a validated method of picking up severe ill-
ness and should continue to be used as a means of
detecting community infection and directing referral,
with clinical diagnosis being used for confirmation.
Screening should be improved with weekly contact with
the mothers to detect maternally suspected illness.
Greater detail of the symptoms and timescales would en-
hance the accuracy of detection and enable maternal re-
ports of infection to more confidently indicate the total
burden of suspected disease of relevant severity. Finally,
communication between researchers, health care staff,
and participants is crucial, so as to provide high-quality
data on infective morbidity.
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